Loading...

Reata Pharmaceuticals, Inc.

RETANASDAQ
Healthcare
Biotechnology
$172.36
$0.04(0.02%)

Reata Pharmaceuticals, Inc. (RETA) Stock Overview

Explore Reata Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.5/100

Key Financials

Market Cap6.6B
P/E Ratio-20.07
EPS (TTM)$-2.60
ROE0.47%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$276.62

RETA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Reata Pharmaceuticals, Inc. (RETA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $276.62.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -20.07 and a market capitalization of 6.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;